Detalhe da pesquisa
1.
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
J Viral Hepat
; 26(3): 362-372, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30450781
2.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Hepatology
; 68(4): 1298-1307, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672891
3.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Clin Infect Dis
; 67(7): 1010-1017, 2018 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566246
4.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Ann Hepatol
; 17(6): 959-968, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30600291
5.
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
J Infect Dis
; 215(4): 599-605, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329334
6.
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Gastroenterology
; 150(7): 1590-1598, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26976799
7.
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
J Hepatol
; 64(2): 301-307, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26476290
8.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
J Hepatol
; 62(2): 294-302, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25239078
9.
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Blood
; 121(23): 4635-46, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23589670
10.
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Liver Int
; 35(1): 108-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24517252
11.
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Liver Int
; 35(1): 79-89, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24814388
12.
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrob Agents Chemother
; 58(2): 1136-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295986
13.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811112
14.
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Gastroenterology
; 142(4): 790-5, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22248659
15.
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
J Hepatol
; 55(5): 972-9, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21354234
16.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Lancet
; 376(9751): 1467-75, 2010 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20951424
17.
Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
Antimicrob Agents Chemother
; 54(10): 4059-63, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20696881
18.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
Kidney Int Rep
; 4(2): 257-266, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30775622
19.
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Eur J Gastroenterol Hepatol
; 30(9): 1073-1076, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29762255
20.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Open Forum Infect Dis
; 4(3): ofx154, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948180